EGFR and p53 status of pulmonary pleomorphic carcinoma: Implications for EGFR tyrosine kinase inhibitors therapy of an aggressive lung malignancy

Annals of Surgical Oncology

Volumn 18, Issue 10, 2011, Pages 2952-2960

  Chang, Yih Leong ^a   Wu, Chen Tu ^a   Shih, Jin Yuan ^a   Lee, Yung Chie ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GENOMIC DNA; PARAFFIN; PROTEIN P53; PROTEIN TYROSINE KINASE INHIBITOR;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CORRELATION ANALYSIS; EXON; FEMALE; GENE; GENE AMPLIFICATION; GENE DELETION; HISTOGENESIS; HUMAN; HUMAN TISSUE; KRAS GENE; LUNG CARCINOMA; LYMPH NODE METASTASIS; MALE; MICRODISSECTION; POINT MUTATION; PROTEIN FUNCTION; PULMONARY PLEOMORPHIC CARCINOMA; SEX DIFFERENCE; SMOKING HABIT; SOMATIC MUTATION; TUMOR VOLUME;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; DNA, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SMALL CELL LUNG CARCINOMA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 80052696734     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-011-1621-7     Document Type: Article

References (44)

1. YL Chang YC Lee JY Shih CT Wu 2001 Pulmonary pleomorphic (spindle) cell carcinoma: peculiar clinicopathologic manifestations different from ordinary non-small cell carcinoma Lung Cancer. 34 91 97 11557118 10.1016/S0169-5002(01) 00224-0 1:CAS:528:DC%2BD3MXlvFCqsLs%3D
2. T Yuki T Sakuma C Ohbayashi, et al. 2007 Pleomorphic carcinoma of the lung: a surgical outcome J Thorac Cardiovasc Surg. 134 399 404 17662779 10.1016/j.jtcvs.2007.04.018 (Pubitemid 47088618)
3. K Ito S Oizumi S Fukumoto, et al. 2010 Clinical characteristics of pleomorphic carcinoma of the lung Lung Cancer. 68 204 210 19577320 10.1016/j.lungcan.2009.06.002
4. Corrin B, Chang YL, Rossi G, et al. Sarcomatoid carcinoma. In: Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC, editors. Pathology and genetics of tumors of the lung, pleura, thymus and heart. Lyon: IARC Press; 2004. p. 53-8.
5. NF Fishback WD Travis CA Moran DG Guinee Jr WF McCarthy MN Koss 1994 Pleomorphic (spindle/giant cell) carcinoma of the lung. A clinicopathologic correlation of 78 cases Cancer 73 2936 2945 8199991 10.1002/1097-0142(19940615) 73:12<2936::AID-CNCR2820731210>3.0.CO;2-U 1:STN:280:DyaK2c3lvVKmuw%3D%3D (Pubitemid 24170766)
6. G Rossi A Cavazza N Sturm, et al. 2003 Pulmonary carcinomas with pleomorphic, sarcomatoid, or sarcomatous elements: a clinicopathologic and immunohistochemical study of 75 cases Am J Surg Pathol. 27 311 324 12604887 10.1097/00000478-200303000-00004 (Pubitemid 36245796)
7. T Mochizuki G Ishii K Nagai, et al. 2008 Pleomorphic carcinoma of the lung: clinicopathologic characteristics of 70 cases Am J Surg Pathol. 32 1727 1735 18769330 10.1097/PAS.0b013e3181804302
8. A Ushiki T Koizumi N Kobayashi, et al. 2009 Genetic heterogeneity of EGFR mutation in pleomorphic carcinoma of the lung: response to gefitinib and clinical outcome Jpn J Clin Oncol. 39 267 270 19155283 10.1093/jjco/hyn155
9. HM Bae HS Min SH Lee, et al. 2007 Palliative chemotherapy for pulmonary pleomorphic carcinoma Lung Cancer. 58 112 115 17574296 10.1016/j.lungcan.2007. 05.006 (Pubitemid 47379968)
10. S Yamamoto D Hamatake T Ueno, et al. 2007 Clinicopathological investigation of pulmonary pleomorphic carcinoma Eur J Cardiothorac Surg. 32 873 876 17942316 10.1016/j.ejcts.2007.09.010 (Pubitemid 350052576)
11. DS Salomon R Brandt F Ciardiello N Normanno 1995 Epidermal growth factor-related peptides and their receptors in human malignancies Crit Rev Oncol Hematol. 19 183 232 7612182 10.1016/1040-8428(94)00144-I 1:STN:280: DyaK2Mzjs1KgsQ%3D%3D
12. FR Hirsch M Varella-Garcia PA Bunn Jr, et al. 2003 Epidermal growth factor receptor in non-small cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis J Clin Oncol. 21 3798 3807 12953099 10.1200/JCO.2003.11.069 1:CAS:528:DC%2BD2cXpsVKisL8%3D (Pubitemid 46606235)
13. G Selvaggi S Novello V Torri, et al. 2004 Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small cell lung cancer Ann Oncol. 15 28 32 14679115 10.1093/annonc/mdh011 1:STN:280:DC%2BD3srps1Kntw%3D%3D (Pubitemid 38139599)
14. MA Olayioye RM Neve HA Lane NE Hynes 2000 The erb B signaling network: receptor heterodimerization in development and cancer EMBO J. 19 3159 3167 10880430 10.1093/emboj/19.13.3159 1:CAS:528:DC%2BD3cXlt1ajtLY%3D (Pubitemid 30428195)
15. A Levitzki A Gazit 1995 Tyrosine kinase inhibition: an approach to drug development Science. 267 1782 1788 7892601 10.1126/science.7892601 1:CAS:528:DyaK2MXkslWgtL4%3D
16. ML Levitt PP Koty 1999 Tyrosine kinase inhibitors in preclinical development Invest New Drugs. 17 213 226 10665475 10.1023/A:1006372102543 1:CAS:528:DC%2BD3cXhtFart7g%3D (Pubitemid 30037955)
17. T Mitsudomi Y Yatabe 2007 Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer Cancer Sci. 98 1817 1824 17888036 10.1111/j.1349-7006.2007.00607.x 1:CAS:528:DC%2BD2sXhsVahtbbF (Pubitemid 350002184)
18. YL Chang CT Wu SC Lin CF Hsiao YS Jou YC Lee 2007 Clonality and prognostic implications of p53 and epidermal growth factor receptor somatic aberrations in multiple primary lung cancers Clin Cancer Res. 13 52 58 17200338 10.1158/1078-0432.CCR-06-1743 1:CAS:528:DC%2BD2sXotlei (Pubitemid 46121852)
19. H Shigematsu L Lin T Takahashi, et al. 2005 Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers J Natl Cancer Inst. 97 339 346 15741570 10.1093/jnci/dji055 1:CAS:528:DC%2BD2MXitV2jsb4%3D (Pubitemid 40425952)
20. BE Johnson PA Janne 2005 Epidermal growth factor receptor mutations in patients with non-small cell lung cancer Cancer Res. 65 7525 7529 16140912 1:CAS:528:DC%2BD2MXpslait7s%3D (Pubitemid 41297219)
21. CA Finlay PW Hinds AJ Levine 1989 The p53 proto-oncogene can act as a suppressor of transformation Cell. 57 1083 1093 2525423 10.1016/0092-8674(89) 90045-7 1:CAS:528:DyaL1MXkslagtb8%3D (Pubitemid 19169804)
22. D Sidransky T Mikkelsen K Schwechheimer ML Rosenblum W Cavanee B Vogelstein 1992 Clonal expansion of p53 mutant cells is associated with brain tumour progression Nature. 355 846 847 1311419 10.1038/355846a0 1:CAS:528:DyaK38XhslWhtL4%3D
23. CW Miller K Simon A Aslo, et al. 1992 P53 mutations in human lung tumors Cancer Res. 52 1695 1698 1312896 1:CAS:528:DyaK38XitFajtLo%3D
24. Y Sekido KM Fong JD Minna 2003 Molecular genetics of lung cancer Annu Rev Med. 54 73 87 12471176 10.1146/annurev.med.54.101601.152202 1:CAS:528:DC%2BD3sXit1ejs7k%3D (Pubitemid 37386386)
25. American Joint Committee on Cancer. Lung. In: Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. AJCC cancer staging manual. 7th ed. New York: Springer; 2010. p. 253-70.
26. K Sugio Y Kishimoto A Virmani JY Hung AF Gazdar 1994 K-ras mutations are a relatively late event in the pathogenesis of lung carcinomas Cancer Res. 54 5811 5815 7954406 1:CAS:528:DyaK2cXmvFyitb8%3D (Pubitemid 24375211)
27. H Linardou IJ Dahabreh D Kanaloupiti, et al. 2008 Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer Lancet Oncol. 9 962 972 18804418 10.1016/S1470-2045(08)70206-7 1:CAS:528:DC%2BD1cXhtFOmurvJ
28. F Cappuzgo FR Hirsch E Rossi, et al. 2005 Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small cell lung cancer J Natl Cancer Inst. 97 643 655 10.1093/jnci/dji112 (Pubitemid 40812628)
29. M Varella-Garcia J Diebold DA Eberhard, et al. 2009 EGFR fluorescence in situ hybridization assay: guidelines for application to non-small-cell lung cancer J Clin Pathol. 62 970 977 19861557 10.1136/jcp.2009.066548 1:CAS:528:DC%2BC3cXkvVejsLg%3D
30. CL Arteaga 2002 Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia Semin Oncol. 29 3 9 12422308 1:CAS:528:DC%2BD38XoslWitbg%3D (Pubitemid 35191041)
31. TJ Lynch DW Bell R Sordella, et al. 2004 Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med. 350 2129 2139 15118073 10.1056/NEJMoa040938 1:CAS:528:DC%2BD2cXktF2js7c%3D (Pubitemid 38637993)
32. A Italiano AB Cortot M Ilie, et al. 2009 EGFR and KRAS status of primary sarcomatoid carcinomas of the lung: implications for anti-EGFR treatment of a rare lung malignancy Int J Cancer. 125 2479 2482 19681124 10.1002/ijc.24610 1:CAS:528:DC%2BD1MXhtFOkt77E
33. T Kosaka Y Yatabe H Endoh H Kuwano T Takahashi T Mitsudomi 2004 Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications Cancer Res. 64 8919 8923 15604253 10.1158/0008-5472.CAN- 04-2818 1:CAS:528:DC%2BD2cXhtVOmsL3P (Pubitemid 39665498)
34. H Shigematsu AF Gazdar 2006 Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers Int J Cancer. 118 257 262 16231326 10.1002/ijc.21496 1:CAS:528:DC%2BD2MXhtlWqs7bF (Pubitemid 41779062)
35. SG Wu YL Chang YC Hsu, et al. 2008 Good response to gefitinib in lung adenocarcinoma of complex epidermal growth factor receptor (EGFR) mutations with the classical mutation pattern Oncologist. 13 1276 1284 19060236 10.1634/theoncologist.2008-0093 1:CAS:528:DC%2BD1MXhvV2nurk%3D
36. JG Paez PA Jänne JC Lee, et al. 2004 EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science. 304 1497 1500 15118125 10.1126/science.1099314 1:CAS:528:DC%2BD2cXksVGmsbs%3D (Pubitemid 38720929)
37. GJ Riely W Pao D Pham, et al. 2006 Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon. 19 and exon 21 mutations treated with gefitinib or erlotinib Clin Cancer Res 12 839 844 16467097 10.1158/1078-0432.CCR-05-1846 1:CAS:528:DC%2BD28XhtFeiurk%3D (Pubitemid 43259866)
38. T Takano Y Ohe H Sakamoto, et al. 2005 Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer J Clin Oncol. 23 6829 6837 15998907 10.1200/JCO.2005.01.0793 1:CAS:528:DC%2BD2MXhtFCrsb3P
39. T Yokoyama M Kondo Y Goto, et al. 2006 EGFR point mutation in non-small cell lung cancer is occasionally accompanied by a second mutation or amplification Cancer Sci. 97 753 759 16863509 10.1111/j.1349-7006.2006.00233.x 1:CAS:528:DC%2BD28Xot1Cnurk%3D (Pubitemid 43983788)
40. I Chiba T Takahashi MM Nau, et al. 1990 Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group Oncogene. 5 1603 1610 1979160 1:CAS:528:DyaK3MXjslSlsQ%3D%3D
41. O Vatan R Bilaloglu B Tunca, et al. 2007 Low frequency of p53 and k-ras codon 12 mutations in non-small cell lung carcinoma (NSCLC) tumors and surgical margins Tumori. 93 473 477 18038880 1:CAS:528:DC%2BD2sXhsVyjurrK (Pubitemid 350203921)
42. RM Przygodzki MN Koss CA Moran, et al. 1996 Pleomorphic (giant and spindle cell) carcinoma is genetically distinct from adenocarcinoma and squamous cell carcinoma by K-ras-2 and p53 analysis Am J Clin Pathol. 106 487 492 8853037 1:STN:280:DyaK2s%2FgsFOgug%3D%3D (Pubitemid 26332999)
43. YC Lee YL Chang SP Luh JM Lee JS Chen 1999 Significance of P53 and RB protein expression in surgically treated non-small cell lung cancers Ann Thorac Surg. 68 343 348 10475393 10.1016/S0003-4975(99)00618-9 1:STN:280: DyaK1Mvgt1ekug%3D%3D (Pubitemid 29521073)
44. D Dias-Santagata S Akhavanfard SS David, et al. 2010 Rapid targeted mutational analysis of human tumors: a clinical platform to guide personalized cancer medicine EMBO Mol Med. 2 146 158 20432502 10.1002/emmm.201000070